EMB-01
- Generic Name
- EMB-01
- Drug Type
- Biotech
- Unique Ingredient Identifier
- G86X5QQ7M5
- Background
EMB-01 is under investigation in clinical trial NCT03797391 (A Dose Escalation Study of EMB-01 in Participants With Advanced/metastatic Solid Tumors).
EMB-01 in Combination With Osimertinib in Patients With EGFR Mutant Lung Cancer
- Conditions
- Stage III Lung Cancer AJCC v8EGFR Mutation-Related TumorsStage IIIB Lung Cancer AJCC v8Metastatic Lung Non-Small Cell CarcinomaAdvanced Lung Non-Small Cell CarcinomaStage IIIA Lung Cancer AJCC v8Stage IVB Lung Cancer AJCC v8Stage IV Lung Cancer AJCC v8Stage IVA Lung Cancer AJCC v8
- Interventions
- First Posted Date
- 2022-08-12
- Last Posted Date
- 2023-06-01
- Lead Sponsor
- Shanghai EpimAb Biotherapeutics Co., Ltd.
- Target Recruit Count
- 115
- Registration Number
- NCT05498389
- Locations
- 🇺🇸
Chao Family Comprehensive Cancer Center, University of California Irvine School of Medicine, Orange, California, United States
🇨🇳Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers
- Conditions
- NeoplasmsNeoplasm MetastasisMetastatic Gastrointestinal Carcinoid Tumor
- Interventions
- First Posted Date
- 2022-01-04
- Last Posted Date
- 2024-08-26
- Lead Sponsor
- Shanghai EpimAb Biotherapeutics Co., Ltd.
- Target Recruit Count
- 152
- Registration Number
- NCT05176665
- Locations
- 🇨🇳
Nanfang Hospital, Guangzhou, Guangdong, China
🇨🇳West China Hospital, Sichuan University, Chengdu, China
🇨🇳The Sixth Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China
Efficacy and Safety of Combination EMB-001 as a Potential Smoking Cessation Treatment
- First Posted Date
- 2021-04-30
- Last Posted Date
- 2021-05-28
- Lead Sponsor
- Rose Research Center, LLC
- Target Recruit Count
- 25
- Registration Number
- NCT04868253
- Locations
- 🇺🇸
Rose Research Center, Raleigh, North Carolina, United States
A Dose Escalation With Expansion Study of EMB-01 in Participants With Advanced/Metastatic Solid Tumors
- Conditions
- NeoplasmsNon-Small-Cell Lung CancerNeoplasm Metastasis
- Interventions
- First Posted Date
- 2019-01-09
- Last Posted Date
- 2023-05-31
- Lead Sponsor
- Shanghai EpimAb Biotherapeutics Co., Ltd.
- Target Recruit Count
- 186
- Registration Number
- NCT03797391
- Locations
- 🇺🇸
Gabrail Cancer Center Research, Canton, Ohio, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇨🇳Shanghai Chest Hosptial, Shanghai, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.